UPDATE: Cepheid Wins FDA Clearance for Xpert CT/NG
December 27, 2012 at 16:13 PM EST
Cepheid (NASDAQ: CPHD ) today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert^® CT/NG. Running on Cepheid's GeneXpert^® Systems, Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). For the first